Seeking Alpha

Michael Fuller

 
View as an RSS Feed
View Michael Fuller's Comments BY TICKER:
Latest  |  Highest rated
  • Uni-Pixel - An Enigma Worth Betting On [View article]
    Nice reply and agree! Let's split that difference.
    Jun 19 11:46 AM | Likes Like |Link to Comment
  • Celsion: 50% Downside After The HEAT Trial Failed [View article]
    Doesn't change the fact that your article on UNXL was full of fabrications. Share price isn't proof of truth.

    I've only been trading it and have no long positions but your articles should make you ashamed when you visit your mother.
    Jun 14 11:02 PM | 1 Like Like |Link to Comment
  • Celsion: 50% Downside After The HEAT Trial Failed [View article]
    Second time Adam and I have agreed. I also called the failure before the trial data was revealed. Tried to get a few friends out before the fall but... oh well.

    I owe you two beers Adam.
    Jun 13 10:49 AM | Likes Like |Link to Comment
  • Celsion: 50% Downside After The HEAT Trial Failed [View article]
    LOL. I'm in agreement with Adam! OMG!

    Adam, I owe you a beer for this momentous occasion. At least when you and I disagree, we do so in plain sight with our names on the line.
    Jun 13 10:48 AM | Likes Like |Link to Comment
  • Was The Aetna News Overblown? Blue Cross Blue Shield Supports Questcor's H.P. Acthar Gel [View article]
    gdavidson1731,

    Are you being real here? or are you a short just trying to stir things up? It was a momentary drop of a small amount of shares, when no one was looking. Once someone did notice cheap shares were being made available by the shorts, right back up.
    Jun 12 05:58 PM | 1 Like Like |Link to Comment
  • After-hours top gainers, as of 5:15 p.m.: SWY +30%. SPRD +25%. PVH +7%. PSMI +6%. SVU +6%.
    After-hours top losers: SIGM -8%. QCOR -7%. SQNM -5%. ECYT -3%. VLCCF -3%[View news story]
    Thousands of emails sent, on a few trades moving prices momentarily. Amazing!

    Seeking Alpha's new motto... "Made ya look.... neener neener neener..."
    Jun 12 05:53 PM | 1 Like Like |Link to Comment
  • Jefferies analyst Biren Amin weighs in on Questcor (QCOR +21%), saying that some of today's move has to do with the short interest being around 32% of its float, but adds that its purchase of Synacthen removes an overhang and has the potential to eliminate a competitive threat going forward. For that to happen however, trials from Synacthen and Synacthen Depot in rheumatology, multiple sclerosis, IS and NS will need to demonstrate solid efficacy and safety within the US. Amin maintains a Buy on the shares with a $38 price target. [View news story]
    I think he is viewing it more as a defensive play and hasn't done the research to understand it was also a huge offensive play. Defensive play in the short term BUT this is a different chemical entity with different indications. It cannot be used for IS because of the benzyl. It can be used for some other orphan statuses though, and with more clinical trials, will have it's own orphan designation.

    Offensive play will start to be figured out by analysts and shorts in the coming months.
    Jun 11 07:44 PM | 1 Like Like |Link to Comment
  • Buy Rubicon Ahead Of Cyclical And Secular Upturn [View article]
    Funny...
    Jun 9 10:34 PM | Likes Like |Link to Comment
  • Questor(QCOR) - United Health Confirms Coverage Of Acthar For All Indications 6/1/2013 [View instapost]
    Always nice to break news and see it flourish into Options Cast, Benzinga, Street Insider, etc.
    Jun 7 01:22 PM | Likes Like |Link to Comment
  • Questcor's Upcoming First Quarter Report: An Investor Reference Guide [View article]
    For those that missed my very early morning tweet breaking the United Health news.

    Michael Fuller ‏@MKerryFuller 2h
    $QCOR United Health confirms continuing coverage for all indications June 1st, 2013

    http://bit.ly/17ugmGL
    Jun 7 11:26 AM | 1 Like Like |Link to Comment
  • Questcor Pharmaceuticals: How Can Such A Profitable Company Be So Risky? [View article]
    Who did? The author? No, been debunked many times even before last October.

    If you were talking about livatyl, who posted right above you... yep, and that's not even the half of it. News on trials, scripts, etc. all coming out starting this week.
    Jun 6 04:44 PM | 2 Likes Like |Link to Comment
  • Was The Aetna News Overblown? Blue Cross Blue Shield Supports Questcor's H.P. Acthar Gel [View article]
    Oops... had seeking alpha open in two windows and posted a UNXL here. Sorry to Author and readers.
    Jun 5 06:37 AM | 1 Like Like |Link to Comment
  • Buy Rubicon Ahead Of Cyclical And Secular Upturn [View article]
    Eeek! You just demonstrated even less knowledge regarding the companies, by talking about the fundamentals.

    Well, I'm unclicking the 'track article' checkmark. Not going to be worth following the comments here.
    Jun 4 01:25 PM | 4 Likes Like |Link to Comment
  • Buy Rubicon Ahead Of Cyclical And Secular Upturn [View article]
    LOL. Author compares a copper wire mesh grid for sensing touch, to a piece of glass and comes to the conclusion UNXLs product is yet unproven.

    Did he put UNXL in his article just to get clicks, or did he really think those two things were the same.

    When shorts were attacking QCOR, they would do silly things like this and state that Acthar was a dietary supplement you buy at GNC. I'm reminded of those times 6 months ago.

    As for the rest of the article, that one glaring piece of misinformation calls into question everything else, so I didn't bother to read it.
    Jun 4 01:12 PM | 6 Likes Like |Link to Comment
  • Was The Aetna News Overblown? Blue Cross Blue Shield Supports Questcor's H.P. Acthar Gel [View article]
    LOL. A bad analogy and you stretch it to that. I personally know most of the commenters and their backgrounds in the industry.

    But hey, go with you stretch of the imagination.
    Jun 4 09:59 AM | 2 Likes Like |Link to Comment
COMMENTS STATS
298 Comments
481 Likes